|
Palo Alto, CA, April 9, 2003 — Telik, Inc. (Nasdaq:
TELK) announced positive interim results from the ongoing Phase
1-2a clinical trial of its TLK199 product candidate in patients
with myelodysplastic syndrome (MDS), a form of pre-leukemia. The
abstract for the study was published in the March 2003 Proceedings
of the Annual Meeting of the American Association for Cancer Research
(AACR).
The open label, multicenter dose escalation trial is designed to
evaluate safety, pharmacokinetics, pharmacodynamics and efficacy.
Twelve MDS patients had been enrolled in the dose-escalation stage
of the trial at the time of interim analysis. TLK199 has been well-tolerated,
and the maximum tolerated dose has not been reached.
Evidence of clinical activity has been observed in 50% of evaluable
patients. All responders showed clinically significant increases
in at least two of the three major blood elements (white cells,
red cells and platelets), with one patient showing increases in
all three elements. This patient also had a significant decrease
in red cell transfusion requirements, an important clinical benefit.
In addition, one patient with a particularly advanced type of MDS
had a decrease in levels of pre-leukemic cells, consistent with
a direct anti-proliferative effect of TLK199.
"These interim results suggest that TLK199 may act at a point
in the bone marrow differentiation cycle that affects the subsequent
development of all three major blood elements," said Gail L.
Brown, M.D., senior vice president and chief medical officer. "Clinical
activity has been seen even at the lowest dose levels, and these
exciting preliminary findings are being further explored as the
dose escalation continues."
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TLK286, a tumor activated small molecule drug that is in a Phase
3 registration clinical trial in ovarian cancer and in clinical
trials in non-small cell lung, colorectal and breast cancer. TLK199
is in a Phase 1-2a trial in myelodysplastic syndrome, a form of
pre-leukemia, and may have potential in other hematologic conditions
associated with cytopenia, including chemotherapy-induced cytopenia.
Telik’s product candidates were discovered using its proprietary
drug discovery technology, TRAP, which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information
is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding the potential
for TLK286 or TLK199 to treat one or more types of cancer. Telik
can give no assurance with regard to these statements. TLK286 and
TLK199 are in clinical development and have not been approved for
marketing, and there can be no assurance that the clinical trials
required to successfully develop these compounds will have a positive
outcome, or that regulatory approval will be obtained. Telik is
reliant on external manufacturing of TLK286 and TLK199. More detailed
information regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in
this press release may be found in Telik’s periodic filings
with the Securities and Exchange Commission. Telik assumes no obligation
to update any information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
